Cardinal Health, Inc. Q2 FY26 Earnings Analysis

- Specialty business expected to grow over 20% in revenue, with Specialty revenue forecasted to exceed $50 billion in fiscal 2026 (Pages 3,7). - Continued strong demand and demographic trends support positive outlook in Pharmaceutical and Specialty Solutions segments (Page 4). - Growth in other businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics with revenue up 31% and profit up 34% (Pages 3,7). - GMPD segment projecting 1% to 3% revenue growth; focus on cost efficiencies and supply chain resilience (Page 4). - Positive contribution expected from annualization of Solaris acquisition and synergy realization (Page 4). - Ongoing investments in technology and teams targeted for future growth and operational efficiency (Page 7). - The company remains confident in long-term EPS growth targets of 12% to 14%, reflecting sustained volume and revenue growth (Pages 6,12).

- Confident in long-term targets with expected 12% to 14% non-GAAP EPS growth. - Fiscal 2026 non-GAAP EPS outlook raised to $10.70–$10.80, reflecting 30%–31% annual growth. - Segment profit growth in Pharma improved to 22%–23% for fiscal 2026, higher than prior guidance. - Continued strong performance in Specialty and other growth businesses, with >20% revenue growth and increased profit guidance. - Ongoing operational execution and synergy realization anticipated to support profit improvements. - Strategic investments in technology and team aimed at positioning for future growth. - Expect robust cash flow generation to support disciplined capital allocation including share repurchases. - Monitoring factors like tariffs and macroeconomic impacts, but expect manageable influence. - Fiscal 2027 planning underway with positive outlook on demand, demographics, and operational efficiency, detailed guidance to come in Q4 call.

- Investing in infrastructure, technology, and people to improve core Pharma segment, including automation and productivity initiatives in distribution centers. - Expansion of at-Home Solutions network capacity, offerings, and technology to drive efficiency and customer experience. - Progressing with a new Sacramento distribution center lease to better serve West Coast customers. - Expansion of Actinium-225 production capabilities at Center for Theranostics to support growing demand for targeted cancer therapies. - Continued investments in technology and core distribution footprint to support growth across Specialty and other businesses. - Focused SG&A investments, particularly in technology and team, to position for future growth while being purposeful and disciplined. - Potential bolt-on acquisitions in Specialty areas such as autoimmune and urology, pursued with discipline at the right timing and price.

- There is no direct mention of new fundraising through debt or equity in the provided pages. - The company increased its outlook for interest and other expenses to approximately $340 million (up from $325 million) due to Q3 adjustments, mostly offset in tax and net neutral to the enterprise (Page 4). - Share repurchase activity is ongoing, with $1 billion repurchased fiscal year-to-date, exceeding the baseline target by $250 million (Page 2). - The company emphasizes disciplined capital allocation and confidence in cash flow generation, with raised adjusted free cash flow guidance to $3.3 billion - $3.7 billion (Page 4). - No specific plans or commentary about raising new debt or equity funding were disclosed in the included transcript portions.

The provided transcript does not explicitly mention current or expected orderbook or pending orders details. However, there is relevant information related to business volumes and contract ramp-ups that may indirectly reflect on order flow: - Solaris distribution volume is currently in the process of ramping up with the pharma business; impact on fiscal ’26 expected to be not material but positive moving forward (Page 14). - Ion and GIA distribution contracts have been achieved and volumes are coming in as expected, but their impact is modeled separately from financial guidance (Page 14). - Specialty business including recent acquisitions (Ion, Solaris, GIA) is growing strongly and performing as expected (Page 6, 15). - There is no explicit mention of outstanding or pending orders, but broad specialty and pharma demand is described as resilient and strong across segments (Pages 6, 13, 15). - The company expects continued growth and strong demand outlook in Pharmaceutical and Specialty Solutions segments (Page 4). No specific numeric orderbook or backlog figures are disclosed.